Natera wins Japan approval and Guggenheim targets Natera stock at USD 475

Published on 10/06/2026 at 16:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Japan cleared Signatera for companion diagnostic use on October 5, 2026. Natera stock was last EUR 382.70 on October 6, 2026, up 0.95 percent.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) secured Japanese clearance for its Signatera test as a companion diagnostic on October 5, 2026, while Guggenheim raised its target for Natera from USD 360 to USD 475 in a note dated October 1, 2026. The two developments put regulatory expansion and valuation expectations side by side.

Japan expands Signatera reach

According to Simply Wall St on October 5, 2026, Japan's regulator cleared Signatera for use in treatment decisions involving muscle-invasive bladder cancer and adjuvant atezolizumab. The approval gives Natera another regulatory foothold for its molecular residual disease testing platform.

Natera describes its business as cell-free DNA testing across women's health, oncology and organ health. Its platform includes Signatera, Panorama and Prospera, while its laboratories operate in Austin and San Carlos.

Revenue growth meets a valuation test

Natera's second-quarter 2026 revenue was USD 752.75 million, up 37.7 percent from the same quarter a year earlier, according to MarketBeat. The company reported a loss of USD 0.47 per share versus a consensus loss of USD 0.49, a USD 0.02 improvement against expectations.

The same quarter still carried a USD 66.97 million net loss, so the growth story has not yet become a profit story. For investors, the important tension is clear: faster test adoption and regulatory reach must eventually support earnings improvement to justify the higher valuation expectations.

Target rises above recent trading

Yahoo Finance lists Guggenheim's October 1, 2026 action as a Buy rating maintained alongside the target increase from USD 360 to USD 475. That target sits above the latest USD 398.52 primary-market quote from the finance data tool, while the USD 167.33 to USD 437.41 52-week range shows how sharply the valuation has expanded.

MarketBeat reported an average analyst target of USD 341.55 on October 6, 2026, below Guggenheim's new target. The disagreement makes the next earnings update important because the market will test whether revenue growth can narrow the gap between bullish targets and current profitability.

Tradegate quote sets the reference

Natera was last at EUR 382.70 on Tradegate on October 6, 2026 at 10:44 a.m. CEST, plus 0.95 percent. Price source: substitute price Tradegate, Lang & Schwarz without data set.